BioNTech SE - ADR BNTX shares are trading higher by 5.5% at $350 Friday morning after Canaccord Genuity maintained a Buy rating on the stock and raised its price target from $240 to $450. The German biotechnology company has received a number of analyst rating updates over the past week.
On August 11th, HC Wainwright & Co. analyst Robert Burns maintained BioNTech with a Neutral and raises the price target from $194 to $330.
On August 11th, Bryan Garnier analyst Olga Smolentseva upgraded BioNTech from Neutral to Buy and announced a $451 price target.
On August 13th, SVB Leerink analyst Daina Graybosch maintained BioNTech with a Market Perform and raised the price target from $159 to $293.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19.
BioNTech has a 52-week high of $464 and a 52-week low of $54.10.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
